The antihypertensive chromogranin A peptide catestatin acts as a novel endocrine/paracrine modulator of cardiac inotropism and lusitropism

Endocrinology

Volumn 149, Issue 10, 2008, Pages 4780-4793

  Angelone, Tommaso ^a   Quintieri, Anna Maria ^a   Brar, Bhawanjit K ^b   Limchaiyawat, Pauline T ^b   Tota, Bruno ^a   Mahata, Sushil K ^b   Cerra, Maria Carmela ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA 2 ADRENERGIC RECEPTOR; CATESTATIN; CHROMOGRANIN A; CYCLIC GMP; NITRIC OXIDE; PHOSPHOLAMBAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; HYPERTENSION; INOTROPISM; MALE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CHROMOGRANIN A; CORONARY CIRCULATION; ENDOTHELIN-1; HEART RATE; HUMANS; HYPERTENSION; ISOPROTERENOL; MALE; MYOCARDIAL CONTRACTION; PARACRINE COMMUNICATION; PEPTIDE FRAGMENTS; PERFUSION; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM; VASODILATION; VENTRICULAR PRESSURE;

EID: 53249145571     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-0318     Document Type: Article

References (56)

1. Winkler H, Fischer-Colbrie R 1992 The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49:497-528
2. Taupenot L, Harper KL, O'Connor DT 2003 Mechanisms of disease: the chromogranin-secretogranin family. N Engl J Med 348:1134-1149
3. Helle KB, Corti A, Metz-Boutigue MH, Tota B 2007 The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 64:2863-2886
4. Tatemoto K, Efendic S, Mutt V, Makk G, Feistner GJ, Barchas JD 1986 Pancreastatin, a novel pancreatic peptide that inhibits insulin secretion. Nature 324:476-478
5. Aardal S, Helle KB, Elsayed S, Reed RK, Serck-Hanssen G 1993 Vasostatins, comprising the N-terminal domain of chromogranin A, suppress tension in isolated human blood vessel segments. J Neuroendocrinol 5:405-412
6. Mahata SK, O'Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, Gill BM, Parmer RJ 1997 Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 100:1623-1633
7. Mahata SK, Mahata M, Wakade AR, O'Connor DT 2000 Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A344-364): identification of amino acid residues crucial for activity. Mol Endocrinol 14:1525-1535
8. Mahata SK, Mahapatra NR, Mahata M, Wang TC, Kennedy BP, Ziegler MG, O'Connor DT 2003 Catecholamine secretory vesicle stimulus-transcription coupling in vivo. Demonstration by a novel transgenic promoter/photoprotein reporter and inhibition of secretion and transcription by the chromogranin A fragment catestatin. J Biol Chem 278:32058-32067
9. Mahata SK, Mahata M, Wen G, Wong WB, Mahapatra NR, Hamilton BA, O'Connor DT 2004 The catecholamine release-inhibitory "catestatin" fragment of chromogranin A: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses. Mol Pharmacol 66:1180-1191
10. Mahata SK 2004 Catestatin - the catecholamine release inhibitory peptide: a structural and functional overview. Curr Med Chem Immun Endocrinol Metab Agents 4:221-234
11. Takiyyuddin MA, Cervenka JH, Sullivan PA, Pandian MR, Parmer RJ, Barbosa JA, O'Connor DT 1990 Is physiologic sympathoadrenal catecholamine release exocytotic in humans? Circulation 81:185-195
12. Koeslag JH, Saunders PT, Wessels JA 1999 The chromogranins and the counter-regulatory hormones: do they make homeostatic sense? J Physiol 517:643-649
13. Ceconi C, Ferrari R, Bachetti T, Opasich C, Volterrani M, Colombo B, Parrinello G, Corti A 2002 Chromogranin A in heart failure: a novel neurohumoral factor and a predictor for mortality. Eur Heart J 23:967-974
14. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G 1995 Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 144:49-59
15. Nobels FR, de Herder WW, Kwekkeboom DJ, Coopmans W, Mulder A, Bouillon R, Lamberts SW 1994 Serum chromogranin A in the differential diagnosis of Cushing's syndrome. Eur J Endocrinol 131:589-593
16. Pieroni M, Corti A, Tota B, Curnis F, Angelone T, Colombo B, Cerra MC, Bellocci F, Crea F, Maseri A 200 Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. Eur Heart J 29:1117-1127
17. Takiyyuddin MA, Baron AD, Cervenka JH, Barbosa JA, Neumann HP, Parmer RJ, Sullivan PA, O'Connor DT 1991 Suppression of chromogranin-A release from neuroendocrine sources in man: pharmacological studies. J Clin Endocrinol Metab 72:616-622
18. Takiyyuddin MA, Parmer RJ, Kailasam MT, Cervenka JH, Kennedy B, Ziegler MG, Lin MC, Li J, Grim CE, Wright FA, O'Connor DT 1995 Chromogranin A in human hypertension. Influence of heredity. Hypertension 26:213-220
19. O'Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ 2002 Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 20:1335-1345
20. Mahapatra NR, O'Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, Staite E, Wu H, Gu Y, Dalton N, Kennedy BP, Ziegler MG, Ross J, Mahata SK 2005 Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 115:1942-1952
21. Wen G, Mahata SK, Cadman P, Mahata M, Ghosh S, Mahapatra NR, Rao F, Stridsberg M, Smith DW, Mahboubi P, Schork NJ, O'Connor DT, Hamilton BA 2004 Both rare and common polymorphisms contribute functional variation at CHGA, a regulator of catecholamine physiology. Am J Hum Genet 74:197-207
22. Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, Mahata M, Kennedy BP, Salem RM, Stridsberg M, Abel K, Smith DW, Eskin E, Schork NJ, Hamilton BA, Ziegler MG, Mahata SK, O'Connor DT 2007 Catecholamine release-inhibitory peptide catestatin [chromogranin A(352-372)]: naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 115: 2271-2281
23. Cerra MC, De Iuri L, Angelone T, Corti A, Tota B 2006 Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart. Basic Res Cardiol 101:43-52
24. Georget M, Mateo P, Vandecasteele G, Lipskaia L, Defer N, Hanoune J, Hoerter J, Lugnier C, Fischmeister R 2003 Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8). FASEB J 17:1380-1391
25. Cappello S, Angelone T, Tota B, Pagliaro P, Penna C, Rastaldo R, Corti A, Losano GA, Cerra MC 2007 Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signalling mechanism. Am J Physiol Heart Circ Physiol 293:H719-H727
26. Vittone L, Mundina-Weilenmann C, Mattiazzi A, Cingolani H 1994 Physiologic and pharmacologic factors that affect myocardial relaxation. J Pharmacol Toxicol Methods 32:7-18
27. Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, Mjos OD, Latchman DS, Lee KF, Vale W 2004 Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 145:24-35
28. Cerra MC, Pellegrino D 2007 Cardiovascular cGMP-generating systems in physiological and pathological conditions. Curr Med Chem 14:585-599
29. Abbott D, Lodola A 1992 The effects of isoproterenol on the isolated perfused rat heart. Res Commun Chem Pathol Pharmacol 76:125-128
30. Asimakis GK, Inners-McBride K, Conti VR, Yang CJ 1994 Transient adrenergic stimulation can precondition the rat heart against postischaemic contractile dysfunction. Cardiovasc Res 28:1726-1734
31. Kennedy BP, Mahata SK, O'Connor DT, Ziegler MG 1998 Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 19:1241-1248
32. Baydoun AR, Peers SH, Cirino G, Woodward B 1989 Effects of endothelin-1 on the rat isolated heart. J Cardiovasc Pharmacol 13:S193-S196
33. Takanashi M, Endoh M 1991 Characterization of positive inotropic effect of endothelin on mammalian ventricular myocardium. Am J Physiol 261:H611-H619
34. Brunner F, Bras-Silva C, Cerdeira AS, Leite-Moreira AF 2006 Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 111:508-531
35. 2+ current in rat ventricular myocytes. J Physiol 531:117-130
36. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA 88:1197-1201
37. Hove-Madsen L, Mery PF, Jurevicius J, Skeberdis AV, Fischmeister R 1996 Regulation of myocardial calcium channels by cyclic AMP metabolism. Basic Res Cardiol 91:1-8
38. Imbrogno S, Angelone T, Corti A, Adamo C, Helle KB, Tota B 2004 Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action. Gen Comp Endocrinol 139:20-28
39. Gallo MP, Levi RC, Ramella R, Brero A, Boero O, Tota B, Alloatti G 2007 Endothelium-derived nitric oxide mediates the anti-adrenergic effect of human vasostatin-1 (CgA 1-76) in rat ventricular myocardium. Am J Physiol Heart Circ Physiol 292:H2906-H2912
40. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, Hobai IA, Lemmon CA, Burnett AL, O'Rourke B, Rodriguez ER, Huang PL, Lima JA, Berkowitz DE, Hare JM 2002 Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 416:337-339
41. Iaccarino G, Ciccarelli M, Sorriento D, Cipolletta E, Cerullo V, Iovino GL, Paudice A, Elia A, Santulli G, Campanile A, Arcucci O, Pastore L, Salvatore F, Condorelli G, Trimarco B 2004 AKT participates in endothelial dysfunction in hypertension. Circulation 109:2587-2593
42. Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC 2005 A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 11:952-958
43. Ciccarelli M, Cipolletta E, Santulli G, Campanile A, Pumiglia K, Cervero P, Pastore L, Astone D, Trimarco B, Iaccarino G 2007 Endothelial β2 adrenergic signaling to AKT: role of Gi and SRC. Cell Signal 19:1949-1955
44. Viatchenko-Karpinski S, Gyorke S 2001 Modulation of the Ca(2+)-induced Ca(2+) release cascade by β-adrenergic stimulation in rat ventricular myocytes. J Physiol 533:837-848
45. Ginsburg KS, Bers DM 2004 Modulation of excitation-contraction coupling by isoproterenol in cardiomyocytes with controlled SR Ca2+ load and Ca2+ current trigger. J Physiol 556:463-480
46. Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, Voisin L, Saba-El-Leil MK, Meloche S, Pouyssegur, Pagès G, De Windt LJ, Doevendans PA, Molkentin JD 2004 MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation 109:1938-1941
47. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molkentin JD 2000 The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19:6341-6350
48. Sugden PH 2001 Signalling pathways in cardiac myocyte hypertrophy. Ann Med 33:611-622
49. Biswas N, Vaingankar SM, Mahata M, Das M, Gayen JR, Taupenot L, Torpey JW, O'Connor DT, Mahata SK 2008 Proteolytic cleavage of human chromogranin A containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin. Endocrinology 149:749-757
50. Mahapatra NR, Mahata M, Mahata SK, O'Connor DT 2006 The chromogranin Afragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters. J Hypertens 24:895-904
51. Schiffrin EL, Deng LY, Larochelle P 1994 Effects of a β-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension 23:83-91
52. Samuels MA 2007 The brain-heart connection. Circulation 116:77-84
53. Steiner HJ, Weiler R, Ludescher C, Schmid KW, Winkler H 1990 Chromogranins A and B are co-localized with atrial natriuretic peptides in secretory granules of rat heart. J Histochem Cytochem 38:845-850
54. Weiergraber M, Pereverzev A, Vajna R, Henry M, Schramm M, Nastainczyk W, Grabsch H, Schneider T 2000 Immunodetection of α1E voltage-gated Ca(2+) channel in chromogranin-positive muscle cells of rat heart, and in distal tubules of human kidney. J Histochem Cytochem 48:807-819
55. Miserez B, Annaert W, Dillen L, Aunis D, De Potter W 1992 Chromogranin Aprocessing in sympathetic neurons and release of chromogranin A fragments from sheep spleen. FEBS Lett 314:122-124
56. Glattard E, Angelone T, Strub JM, Corti A, Aunis D, Tota B, Metz-Boutigue MH, Goumon Y 2006 Characterization of natural vasostatin-containing peptides in rat heart. FEBS J 273:3311-3321